Autologous tumor cells engineered for immune system stimulation can target unique metabolic, genomic, and phenotypic characteristics of cancer cells.
Gary Gordon
Advertisement
Gary Gordon, MD, PhD, is the president of Global Coalition for Adaptive Research.
Articles by Gary Gordon
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Opus Genetics’ OPGx-LCA5 Gene Therapy Shows Sustained Vision Gains Ahead of Phase 3
2
BioPharm Brief: Gene Therapy Progress, FDA Approval, and $103M Funding
3
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
4
Estuary Biotherapeutics Launches With $103 Million for ADPKD Gene Therapy
5